Elevance Health (ELV) has been experiencing noteworthy market fluctuations recently. The bio-tech firm's stock is trading lower today due to various market factors. It's essential to note that the company is about to go ex-dividend. Recently, Barclays has revised the price target of ELV to $373 as part of their analysis. Although the company's performance has been compared multiple times to the S&P 500, Wells Fargo maintains a buy rating on the stock. Furthermore, ELV has reaffirmed their 2025 earnings guidance. Despite softer margin estimates, the company's expansion and earnings pressures have significantly altered its investment story. The company shares have shown a downward trend due to weak Medicaid Margin Out. Over the last year, investors have recorded a 42% loss in ELV. Analysts give mixed ratings amidst weak technicals, with increasing membership growth following their push into digital care and AI. ELV maintains 2025 earnings and expense guidance but registers softer on Medicaid margins. Bernstein maintains a buy rating on ELV, setting a price target of $585. There are speculations about ACA Market Exit in Colorado, indicating broader cost pressures for ELV. It still remains a good choice for long-term investment due to its value-based care strategy. Meanwhile, CEO of the company made a bold stock purchase demonstrating confidence in the firm's future.
Elevance Health ELV News Analytics from Tue, 13 May 2025 07:00:00 GMT to Fri, 05 Sep 2025 14:53:33 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -3
